J Urol Surg 2017; 16: 42-45
Received Date: 30.12.2016
Accepted Date: 13.03.2017

Acıbadem Kadıköy Hastanesi, Üroloji Kliniği, İstanbul, Türkiye


Acıbadem Üniversitesi Tıp Fakültesi, Üroloji Anabilim Dalı, İstanbul, Türkiye


Acıbadem Kadıköy Hastanesi, Radyoloji Kliniği, İstanbul, Türkiye

Initial Outcomes and Assessment of the Transperineal Multiparametric-Magnetic Resonance Imaging/Ultrasonography Fusion Biopsy Method in Diagnosing Clinically-significant Prostate Cancer

Objective: In this study, it was aimed to investigate the success of transperineal multiparametric magnetic resonance imaging (mp-MRI)/transrectal ultrasonography (USG) fusion prostate biopsy method in prostate cancer diagnosis and detection of clinically significant cancer.
Materials and Methods: All patients signed written informed consent then patients with an indication for prostate cancer, therefore biopsy was planned for the last year underwent 3 Tesla mp-MRI retrospectively. All the lesions of patients with Prostate Imaging, Reporting and Data System (PIRADS) 3, 4 and 5 lesions were marked using MIM™ Symphony software by a single radiologist. All patients underwent transperineal MRI/USG fusion biopsy under general anesthesia. In the prostate MRI evaluation of the targeted lesions with a PIRADS score of 3-4-5 were sampled with 2 to 5 cores followed by random biopsies of both of the prostate lobes.
Results: Prostate adenocarcinoma was diagnosed in 20 of 59 patients (33.8%) having fusion biopsy. No difference was observed in prostate-specific antigen levels of patients whose biopsy results were benign and malignant. In 63% of patients, only PIRADS 3 lesions were found, whereas PIRADS 4 and/or 5 lesions were reported in 22 (37%) patients.
The fusion biopsy of PIRADS 3 lesions revealed cancer in 7 patients (19%), of which 6 had clinically-insignificant prostate cancer criteria. Adenocarcinoma was diagnosed in 59% who had PIRADS 4 and/or 5 lesions. All these tumors had clinically-significant cancer characteristics. Lesion-targeted fusion biopsies missed 1 clinically-insignificant adenocarcinoma (1/7; 14.3%), while it did not miss any of the clinically-significant cancers. No infection was seen in post-operative period. Acute urinary retention was developed in 4 patients (6%).
Conclusion: The findings in the initial period give rise to the thought that lesion targeted prostate biopsy method may have a crucial role in especially determining clinically-significant cancer. Prospective randomized studies with larger numbers of patients and especially comparison of different fusion biopsy platforms, are needed in order to assess the diagnostic success of MRI/USG fusion biopsy fully.

Fulltext (Turkish)

Home Archive Search Menu